Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus Toripalimab for Unresectable HCC with PVTT
NCT04069949Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Sichuan University. Primary endpoints: 6-month Progression Free Survival rate and Incidence of Treatment-Emergent Adverse Events up to 6 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04069949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069949.